Amino Acid Supplementation in Continuous Renal Replacement Therapy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Amino acid supplementation (Glavamin, Fresenius Kabi).
- Who it may be relevant to
- Registry conditions: Acute Kidney Injury. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Sweden
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
ICU patients treated with continuous renal replacement therapy is recruited prior to start of treatment. Blood samples are drawn and then dialysis start without amino acid supplementation. After a few hours samples are drawn from blood and dialysate. Then patients are given amino acid supplementation (33.5g/24hrs) for 20-24 hours. New samples are drawn and amino acid supplementation is increased to 67g/24hrs and new samples are drawn after additional 24 hours. Then CRRT will continue with the full amino acid supplementation (standars of care).
Interventions
- Dietary supplement Amino acid supplementation (Glavamin, Fresenius Kabi)
Mixture of amino acids (67 g / 500 ml) given intravenously
Primary outcome measures
- Balance of amino acids [Time frame: After 3 days of dialysis]
Secondary outcome measures (2)
- Amino acid concentration in plasma [Time frame: After 3 days of dialysis]
- Concentration of vitamins and trace elements [Time frame: After 3 days of dialysis]
Eligibility criteria
Inclusion criteria
- Dialysis where amino acid supplementation is planned by treating physician
Exclusion criteria
- Liver failure
- Muscle disease
- Neurodegenerative disease
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Sweden · 1 center
- Karolinska University Hospital — Stockholm
Identifiers
NCT: NCT06835816 · 2023-07570-01